The latest versions are now available on this webpage.
It is important to note that these are all medical documents and therefore must be completed and signed by the treating doctor (e.g. Immunology/Allergy Specialist, Paediatrician or General Practitioner).
To save ASCIA Action Plans that have patient details typed into the text fields you need to "save as" and save to document with a new name (e,g including the patient name).
ASCIA Action Plans should be reviewed when patients are reassessed by their doctor, and each time they obtain a new adrenaline autoinjector prescription, which is approximately every 12 to 18 months. If there are no changes in diagnosis or management the medical information on the ASCIA Action Plan may not need to be updated. However, if the patient is a child, the photo should be updated each time, so they can be easily identified.
Note: The 2015 version of the ASCIA Action Plans are still current and are not intended to be updated this year.
ASCIA Action Plan for Anaphylaxis (personal) for use with EpiPen
Action Plan for Anaphylaxis (general) for use with EpiPen
1. ASCIA Action Plans for Anaphylaxis can be used for individuals with food and insect allergies (ASCIA Action Plans specific for Insect Allergy were discontinued in March 2011).
2. ASCIA Action Plans for Anaphylaxis include instructions on how to use an adrenaline autoinjector and should therefore always be stored with the autoinjector.
3. Adrenaline autoinjectors contain a single, fixed dose of adrenaline and are designed to be used by anyone (medical training is not required), including friends, teacher, childcare worker, parents or patients (if they are not too unwell or too young).
4. It is generally recommended that individuals who carry an adrenaline autoinjector should also wear a medical identification emblem such as a MedicAlert emblem www.medicalert.org.au or www.medicalert.co.nz
5. ASCIA Action Plans for Anaphylaxis have been developed as a concise and easy to follow, single page document to assist in emergency treatment of anaphylaxis. These plans should be used as part of a comprehensive anaphylaxis management plan that includes:
- age appropriate education of allergic individuals and their peers or colleagues (patient support organisations have a range of resources to help educate children)
- training in the recognition and management of allergic reactions (ASCIA has a range of anaphylaxis e-training courses that can be used for this purpose)
- development of strategies to reduce the risk of accidental exposure (refer to ASCIA Guidelines for Anaphylaxis Prevention and patient support organisations)
- an emergency response plan for when exposure does occur (ASCIA Action Plans for Anaphylaxis should be used for this purpose).
Please note: Patients with batches of Anapen 150 and Anapen 300 (that are due to expire in April and June 2015) will need to switch to an alternative brand of adrenaline autoinjector when their devices expire.
For further information contact LINK Healthcare on 1800 777 005 for Australia or +64 9 358 7146 for New Zealand.
Content last updated January 2016